A “high risk drug” doesn’t really make it to phase 3 clinical trials with hundreds of patients when there is a standard of care does it? I’d suggest you go and read the P2 results presentation slowly to see the benefits. Even marginal improvements in reducing protein urea can reduce total time people are on dialysis and extend the time that a healthy kidney lasts.
You are falling back to the “if it’s slightly better is it worth it” and the response is the DSMB would say yes.
A “high risk drug” doesn’t really make it to phase 3 clinical...
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
-0.015(3.19%) |
Mkt cap ! $250.3M | |||
| Open | High | Low | Value | Volume |
| 46.5¢ | 49.0¢ | 45.5¢ | $1.515M | 3.232M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 161532 | 45.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 33998 | 2 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |